Optimization and Characterization of Novel Antifungal Peptides
新型抗真菌肽的优化和表征
基本信息
- 批准号:10476773
- 负责人:
- 金额:$ 30.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-10 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcidsAcuteAddressAminesAntibiotic ResistanceAntifungal AgentsArginineAzolesBasic Amino AcidsBiological AssayCandidaCandida albicansCandida aurisCandida glabrataCandidiasisCell membraneCellsCenters for Disease Control and Prevention (U.S.)ChemistryClinicalCore ProteinCytolysisDataDevelopmentDiseaseDoseDrug InteractionsDrug KineticsDrug resistanceEnsureErythrocytesEvaluationFungal Drug ResistanceGoalsHepG2Hepatitis B VirusHigh Pressure Liquid ChromatographyHumanIn VitroIndustrial fungicideInfectionLifeLinkMammalian CellMicrobiologyMinimum Inhibitory Concentration measurementModificationMorbidity - disease rateMulti-Drug ResistanceMusMycosesNatureParentsPeptide FragmentsPeptide HydrolasesPeptidesPharmaceutical PreparationsPhasePhysiologicalPlasmaPolyenesPopulationPrevalencePrimary carcinoma of the liver cellsProcessPropertyReportingResistanceResistance developmentResistant candidaSafetySelection CriteriaSeriesSerumSmall Business Innovation Research GrantSodium ChlorideSolubilityStructure-Activity RelationshipTestingTherapeuticTimeTissuesToxic effectTriazolesUnited StatesWorkalternative treatmentantimicrobial peptidebasecandidate selectionchemical stabilitycombatcytotoxicitydesignin vitro activityin vivoin vivo evaluationliquid chromatography mass spectrometrymortalitymouse modelnovelprogramsresistant strainresponsescreeningtransmission process
项目摘要
PROJECT SUMMARY / ABSTRACT
Invasive candidiasis is a disease associated with significant morbidity and mortality, with only 3 classes of
antifungals available for treatment. While Candida albicans remains the most common species associated with
this disease, other non-albicans Candida species are emerging or growing in prevalence. The global
emergence of Candida auris, a species with a high rate of multi-drug resistance capable of nosocomial
transmission, and reports of Candida glabrata infections resistant to both azoles and echinocandins, highlight
the critical need for new classes of antifungal drugs that can combat resistance and treat invasive fungal
diseases. AimMax Therapeutics is developing a novel class of promising antifungal peptides that are
differentiated from other antimicrobial peptides in development. Peptides have been considered as promising
therapeutics because of their novel mechanisms of action, rapid cidality, low propensity for resistance
development and low potential for drug-drug interactions. However, there are certain liabilities associated with
historical antimicrobial peptides as systemic therapeutics, including propensity for lysis of human cell
membranes causing toxicity and degradation by circulating proteases and peptidases. Our preliminary studies
have shown that: 1) several of the AimMax peptides have antifungal activity across Candida species, including
activity against resistant strains, 2) this activity is rapidly fungicidal in nature, 3) there is no cell lysis or
intracellular cytotoxicity against human cells and they are well-tolerated following repeat dosing in vivo, 4) they
are salt tolerant and retain activity under physiological conditions, and 5) they can be modified to increase
stability against proteolytic degradation and demonstrate good plasma exposure in vivo. The objective of this
proposal is to optimize the peptides by enhancing antifungal activity and microbiological profile, while
maintaining safety (no toxicity) and minimizing proteolytic instability and undesirable physicochemical
properties. These studies are essential to select potent antifungal peptides to combat resistance and ensure
that they are “druggable” for further development. The objectives of the proposal will be achieved by rational
peptide design and structure-activity relationship analysis using data from a series of in vitro and in vivo
screening assessments. Peptides selected based on pre-determined criteria will undergo expanded
evaluations. Together, these studies will form the basis of candidate selection for further development and
IND-enabling work in a Phase 2 SBIR application. The ultimate goal of this program is to develop a broad-
spectrum antifungal drug that will address the rising threat of drug resistance in Candida species and provide
an alternative treatment option for life-threatening invasive candidiasis.
项目摘要/摘要
侵袭性念珠菌病是一种与显著的发病率和死亡率相关的疾病,仅有3类
可供治疗的抗真菌药物。而白色念珠菌仍然是与
除了这种疾病,其他非白念珠菌物种正在出现或流行。《环球报》
医院内多重耐药率高的金黄色念珠菌的出现
传播,以及对唑类和棘球菌素均耐药的光滑假丝酵母菌感染的报告,重点
迫切需要能够对抗耐药性和治疗侵袭性真菌的新型抗真菌药物
疾病。AimMax治疗公司正在开发一种新的有希望的抗真菌多肽,这些多肽
在开发中区别于其他抗菌肽。多肽一直被认为是很有前途的
治疗药物,因为其作用机制新颖,杀灭迅速,耐药倾向低
发展和药物与药物相互作用的低潜力。然而,存在与以下方面相关的某些责任
抗菌肽作为系统疗法的历史,包括对人类细胞的溶解倾向
通过循环中的蛋白水解酶和肽酶引起毒性和降解的膜。我们的初步研究
研究表明:1)几种AimMax多肽在假丝酵母菌中具有抗真菌活性,包括
对耐药菌株的活性,2)这种活性在性质上是快速杀菌的,3)没有细胞裂解或
对人体细胞的细胞内毒性,在体内重复给药后耐受性良好,4)它们
耐盐并在生理条件下保持活性,以及5)它们可以被修改以增加
对蛋白质降解的稳定性,并在体内表现出良好的血浆暴露。这样做的目的是
建议通过增强抗真菌活性和微生物图谱来优化多肽,而
保持安全(无毒),最大限度地减少蛋白质分解的不稳定性和不受欢迎的物理化学
属性。这些研究对于选择有效的抗真菌多肽来对抗耐药性和确保
他们是“可下药的”,可以进一步发展。提案的目标将通过理性的方式实现
利用一系列体内外数据进行多肽设计和构效关系分析
筛选评估。根据预先确定的标准选择的多肽将进行扩展
评估。总之,这些研究将成为进一步发展和选择候选人的基础
在阶段2 SBIR应用程序中启用IND。这项计划的最终目标是发展一个广泛的-
光谱抗真菌药物,将解决假丝酵母菌不断增加的耐药性威胁,并提供
威胁生命的侵袭性念珠菌病的替代治疗选择。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kara S Keedy其他文献
Kara S Keedy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kara S Keedy', 18)}}的其他基金
Optimization and Characterization of Novel Antifungal Peptides
新型抗真菌肽的优化和表征
- 批准号:
10620239 - 财政年份:2022
- 资助金额:
$ 30.65万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 30.65万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 30.65万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 30.65万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 30.65万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 30.65万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 30.65万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 30.65万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 30.65万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 30.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别:
Operating Grants